Clinical trial
A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to…
NCT00468858 · U.S. Army Medical Research and Development Command, U.S. Fed · Completed
Key facts
| NCT number | NCT00468858 |
|---|---|
| Title | A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children |
| Official title | Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children |
| Lead sponsor | U.S. Army Medical Research and Development Command, U.S. Fed |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dengue Fever, Dengue Hemorrhagic Fever, Dengue Shock Syndrome |
| Intervention type | Biological, Other |
| Interventions | Placebo, T-DEN-Post-Transfection F17, T-DEN-Post-Transfection F19 |
| Enrollment | 636 |
| Start date | Jul 1, 2007 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | May 3, 2007 |
| Last update posted | Jul 2, 2017 |
| Countries | Puerto Rico |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: